{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:01:11Z","timestamp":1793944871515,"version":"4.8.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19bk0104087"],"award-info":[{"award-number":["JP19bk0104087"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP22bk0104145"],"award-info":[{"award-number":["JP22bk0104145"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP15bm0304003"],"award-info":[{"award-number":["JP15bm0304003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-66801-w","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:35:57Z","timestamp":1764164157000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9940-5520","authenticated-orcid":false,"given":"Tomohisa","family":"Iinuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-2871","authenticated-orcid":false,"given":"Takahiro","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tominaga","family":"Fukazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1590-9922","authenticated-orcid":false,"given":"Daisuke","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genta","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momoko","family":"Okoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munechika","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Okura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshie","family":"Sasako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Kira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jafar","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Tsuchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Horikoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoyuki","family":"Hanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8424-5854","authenticated-orcid":false,"given":"Haruhiko","family":"Koseki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9332-3129","authenticated-orcid":false,"given":"Shinichiro","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"66801_CR1","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/nri3328","volume":"12","author":"J Rossjohn","year":"2012","unstructured":"Rossjohn, J., Pellicci, D. G., Patel, O., Gapin, L. & Godfrey, D. I. Recognition of CD1d-restricted antigens by natural killer T cells. Nat. Rev. Immunol. 12, 845\u2013857 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"66801_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3389\/fimmu.2015.00379","volume":"6","author":"C Gottschalk","year":"2015","unstructured":"Gottschalk, C., Mettke, E. & Kurts, C. The role of invariant natural killer T cells in dendritic cell licensing, cross-priming, and memory CD8(+) T cell generation. Front Immunol. 6, 379 (2015).","journal-title":"Front Immunol."},{"key":"66801_CR3","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3389\/fimmu.2013.00409","volume":"4","author":"S Fujii","year":"2013","unstructured":"Fujii, S. et al. NKT cells as an ideal anti-tumor immunotherapeutic. Front Immunol. 4, 409 (2013).","journal-title":"Front Immunol."},{"key":"66801_CR4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00262-007-0373-5","volume":"57","author":"T Uchida","year":"2008","unstructured":"Uchida, T. et al. Phase I study of \u03b1-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer. Cancer Immunol. Immunother. 57, 337\u2013345 (2008).","journal-title":"Cancer Immunol. Immunother."},{"key":"66801_CR5","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1158\/1078-0432.CCR-04-1453","volume":"11","author":"A Ishikawa","year":"2005","unstructured":"Ishikawa, A. et al. A phase I study of \u03b1-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin. Cancer Res. 11, 1910\u20131917 (2005).","journal-title":"Clin. Cancer Res."},{"key":"66801_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1182\/blood-2003-04-1155","volume":"103","author":"M Nieda","year":"2004","unstructured":"Nieda, M. et al. Therapeutic activation of V\u03b124+V\u03b211+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity. Blood 103, 383\u2013389 (2004).","journal-title":"Blood"},{"key":"66801_CR7","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1084\/jem.20042592","volume":"201","author":"DH Chang","year":"2005","unstructured":"Chang, D. H. et al. Sustained expansion of NKT cells and antigen-specific T cells after injection of \u03b1-galactosyl-ceramide loaded mature dendritic cells in cancer patients. J. Exp. Med. 201, 1503\u20131517 (2005).","journal-title":"J. Exp. Med."},{"key":"66801_CR8","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.4049\/jimmunol.0800126","volume":"182","author":"S Motohashi","year":"2009","unstructured":"Motohashi, S. et al. A phase I-II study of \u03b1-galactosylceramide-pulsed IL-2\/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J. Immunol. 182, 2492\u20132501 (2009).","journal-title":"J. Immunol."},{"key":"66801_CR9","doi-asserted-by":"crossref","unstructured":"Toyoda, T. et al. Phase II study of \u03b1-galactosylceramide-pulsed antigen-presenting cells in patients with advanced or recurrent non-small cell lung cancer. J. Immunother. Cancer 8, e000316 (2020).","DOI":"10.1136\/jitc-2019-000316"},{"key":"66801_CR10","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1111\/j.1349-7006.2009.01135.x","volume":"100","author":"N Kunii","year":"2009","unstructured":"Kunii, N. et al. Combination therapy of in vitro-expanded natural killer T cells and \u03b1-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma. Cancer Sci. 100, 1092\u20131098 (2009).","journal-title":"Cancer Sci."},{"key":"66801_CR11","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.clim.2010.11.014","volume":"138","author":"K Yamasaki","year":"2011","unstructured":"Yamasaki, K. et al. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy. Clin. Immunol. 138, 255\u2013265 (2011).","journal-title":"Clin. Immunol."},{"key":"66801_CR12","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI42027","volume":"120","author":"H Watarai","year":"2010","unstructured":"Watarai, H. et al. Murine induced pluripotent stem cells can be derived from and differentiate into natural killer T cells. J. Clin. Invest 120, 2610\u20132618 (2010).","journal-title":"J. Clin. Invest"},{"key":"66801_CR13","doi-asserted-by":"publisher","first-page":"2852","DOI":"10.1002\/stem.2465","volume":"34","author":"D Yamada","year":"2016","unstructured":"Yamada, D. et al. Efficient regeneration of human V\u03b124(+) invariant natural killer T cells and their anti-tumor activity in vivo. Stem Cells 34, 2852\u20132860 (2016).","journal-title":"Stem Cells"},{"key":"66801_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1586\/era.09.113","volume":"9","author":"F Rivera","year":"2009","unstructured":"Rivera, F., Garc\u00eda-Casta\u00f1o, A., Vega, N., Vega-Villegas, M. E. & Guti\u00e9rrez-Sanz, L. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev. Anticancer Ther. 9, 1421\u20131428 (2009).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"66801_CR15","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen, E. E. W. et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393, 156\u2013167 (2019).","journal-title":"Lancet"},{"key":"66801_CR16","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness, B. et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394, 1915\u20131928 (2019).","journal-title":"Lancet"},{"key":"66801_CR17","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med 375, 1856\u20131867 (2016).","journal-title":"N. Engl. J. Med"},{"key":"66801_CR18","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/ni.2731","volume":"14","author":"YJ Lee","year":"2013","unstructured":"Lee, Y. J., Holzapfel, K. L., Zhu, J., Jameson, S. C. & Hogquist, K. A. Steady-state production of IL-4 modulates immunity in mouse strains and is determined by lineage diversity of iNKT cells. Nat. Immunol. 14, 1146\u20131154 (2013).","journal-title":"Nat. Immunol."},{"key":"66801_CR19","doi-asserted-by":"crossref","unstructured":"Matsuda, M. et al. Human NK cell development in hIL-7 and hIL-15 knockin NOD\/SCID\/IL2rgKO mice. Life Sci Alliance 2, e201800195 (2019).","DOI":"10.26508\/lsa.201800195"},{"key":"66801_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"66801_CR21","doi-asserted-by":"publisher","first-page":"1457629","DOI":"10.3389\/fimmu.2024.1457629","volume":"15","author":"M Fang","year":"2024","unstructured":"Fang, M., Allen, A., Luo, C. & Finn, J. D. Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy. Front Immunol. 15, 1457629 (2024).","journal-title":"Front Immunol."},{"key":"66801_CR22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.tibtech.2023.02.003","volume":"41","author":"D Xue","year":"2023","unstructured":"Xue, D. et al. Induced pluripotent stem cell-derived engineered T cells, natural killer cells, macrophages, and dendritic cells in immunotherapy. Trends Biotechnol. 41, 907\u2013922 (2023).","journal-title":"Trends Biotechnol."},{"key":"66801_CR23","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood.2022016205","volume":"141","author":"F Cichocki","year":"2023","unstructured":"Cichocki, F., van der Stegen, S. J. C. & Miller, J. S. Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies. Blood 141, 846\u2013855 (2023).","journal-title":"Blood"},{"key":"66801_CR24","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.stem.2023.02.009","volume":"30","author":"YR Li","year":"2023","unstructured":"Li, Y. R. et al. Advancing cell-based cancer immunotherapy through stem cell engineering. Cell Stem Cell 30, 592\u2013610 (2023).","journal-title":"Cell Stem Cell"},{"key":"66801_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi, A. et al. Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial. Lancet 405, 127\u2013136 (2025).","journal-title":"Lancet"},{"key":"66801_CR26","doi-asserted-by":"crossref","unstructured":"Snyder, K.M. et al. iPSC-derived natural killer cells expressing the Fc\u03b3R fusion CD64\/16A can be armed with antibodies for multitumor antigen targeting. J. Immunother. Cancer 11, e007280 (2023).","DOI":"10.1136\/jitc-2023-007280"},{"key":"66801_CR27","doi-asserted-by":"crossref","unstructured":"Cichocki, F. et al. iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy. Sci. Transl. Med. 12, eaaz5618 (2020).","DOI":"10.1126\/scitranslmed.aaz5618"},{"key":"66801_CR28","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1111\/cas.14374","volume":"111","author":"T Ueda","year":"2020","unstructured":"Ueda, T. et al. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer\/innate lymphoid cells. Cancer Sci. 111, 1478\u20131490 (2020).","journal-title":"Cancer Sci."},{"key":"66801_CR29","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.omto.2022.09.001","volume":"27","author":"S-i Fujii","year":"2022","unstructured":"Fujii, S.-i et al. Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML. Mol. Ther. Oncolytics 27, 315\u2013332 (2022).","journal-title":"Mol. Ther. Oncolytics"},{"key":"66801_CR30","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals, M. et al. Immune-related adverse events of checkpoint inhibitors. Nat. Rev. Dis. Prim. 6, 38 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"66801_CR31","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","volume":"24","author":"H Xu","year":"2019","unstructured":"Xu, H. et al. Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility. Cell Stem Cell 24, 566\u2013578.e567 (2019).","journal-title":"Cell Stem Cell"},{"key":"66801_CR32","doi-asserted-by":"publisher","first-page":"6054","DOI":"10.1158\/1078-0432.CCR-21-1329","volume":"27","author":"F Simonetta","year":"2021","unstructured":"Simonetta, F. et al. Allogeneic CAR invariant natural killer T cells exert potent antitumor effects through host CD8 T-cell cross-priming. Clin. Cancer Res. 27, 6054\u20136064 (2021).","journal-title":"Clin. Cancer Res."},{"key":"66801_CR33","first-page":"24","volume":"7","author":"T Ueda","year":"2023","unstructured":"Ueda, T. et al. Optimization of the proliferation and persistency of CAR T cells derived from human induced pluripotent stem cells. Nat. Biomed. Eng. 7, 24\u201337 (2023).","journal-title":"Nat. Biomed. Eng."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66801-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66801-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66801-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T01:12:56Z","timestamp":1767057176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-66801-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["66801"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-66801-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.K. and S.M. received grants from BrightPath Biotherapeutics Co., Ltd. The other authors declared that they had no relevant conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11666"}}